Research programme: type 2 diabetes mellitus fixed combination therapies - Boehringer Ingelheim
Latest Information Update: 25 Oct 2011
At a glance
- Originator Boehringer Ingelheim
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Phase Unknown Type 2 diabetes mellitus
Most Recent Events
- 20 Oct 2011 Investigation in Type-2 diabetes mellitus (unspecified route)